Myeloma bone disease

Jan Maciej Zaucha

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2001
vol. 5

Send email

Copy url:

abstract:

Myeloma bone disease

Jan Maciej Zaucha

Współcz Onkol (2001) vol. 5, 5 (195-196)

Online publish date: 2003/07/18

View full text Get citation

New insights in the pathophysiology of myeloma bone disease are discussed. Bone disease is the major manifestation of myeloma multiplex. The presence of myeloma cells disturbs the delicate balance between osteolysis and osteosynthesis. Myeloma cells stimulate osteolysis directly through the production of TRANCE/RANKL molecule, which physiologically activates osteoclasts and indirectly through the production of syndecan-1 (CD138), which inhibits osteprotegerin, which in turn acts as a decoy receptor for TRANCE/RANKL. Increased osteoclastic activity leads to release from the bone marrow matrix of several cytokines, which stimulate myloma cells growth. Biphosphonates decrease the incidence and severity of bone lesions, however they do not prolong overall survival.

keywords:

Myeloma bone disease

Jan Maciej Zaucha

Myeloma multiplex, myeloma bone disease